Every material Form 8-K TAO Synergies Inc. has filed with the SEC since August 29, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its December 18, 2025 annual meeting, TAO Synergies stockholders approved raising the share reserve under the 2020 Equity Incentive Plan by 500,000 shares to 3,175,000 shares. They also approved issuing common stock underlying convertible preferred stock and warrants tied to an October 13, 2025 Securities Purchase Agreement, which matters because the issuance could add shares beyond current outstanding totals. Stockholders also elected Bruce T. Bernstein as a director and ratified Stephano Slack LLC as the independent auditor for 2025.
Equity plan reserve increased by 500,000 shares to 3,175,000; vote was 994,315 for, 110,637 against, 22,626 abstentions.
Convertible preferred and warrant share issuance approved under Nasdaq Rule 5635(d): 504,481 for, 78,798 against, 2,109 abstentions.
Bruce T. Bernstein elected director to serve until the 2028 annual meeting, with 1,040,943 votes for and 74,437 against.
Holders of 3,318,341 shares, about 43.18% of outstanding common stock, were present in person or by proxy, establishing a quorum.
TAO Synergies entered into a securities purchase agreement on October 13, 2025, to sell 11,000 Series E convertible preferred shares and warrants in a private placement with expected gross proceeds of $11.0 million, with closing expected October 15, 2025. The preferred stock and warrants are priced at a $8.00 conversion and exercise price, which could add up to 1,375,000 common shares plus warrants for the same number of shares, diluting existing holders if converted.
11,000 Series E preferred shares, stated value $1,000 each, convertible into up to 1,375,000 common shares at $8.00 per share
Warrants to purchase up to 1,375,000 common shares at $8.00, expiring five years after issuance
Expected gross proceeds of $11.0 million; closing expected October 15, 2025, subject to customary conditions
Preferred carries 7% annual cash dividends, rising to 15% after a Triggering Event; stockholder approval sought by December 31, 2025
TAO Synergies announced that directors Jonathan Schechter and Dr. Alan Tuchman resigned from the board on August 28, 2025, with Dr. Tuchman staying on as Chief Medical Officer, and that Robert Ephron was appointed to the board on August 29, 2025. The company also engaged Joseph Jacks as an advisor to its Bittensor-focused digital asset treasury strategy, issuing him warrants for 100,000 shares at $8.40 per share. The filing reports no financial results, and the resignations were described as voluntary and not tied to any disagreement with company operations.
Jonathan Schechter and Dr. Alan Tuchman resigned from the board and all committees on August 28, 2025; both resignations were described as voluntary.
Robert Ephron was appointed to the board on August 29, 2025, and will serve on the audit, compensation and nominating and corporate governance committees.
Joseph Jacks was engaged as an advisor; his one-year consulting agreement includes warrants for 100,000 shares at an exercise price of $8.40, expiring five years from issuance.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TAO Synergies Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →